Startseite Naturwissenschaften Synthesis, antimicrobial and DFT studies of novel fused thiazolopyrimidine derivatives
Artikel Open Access

Synthesis, antimicrobial and DFT studies of novel fused thiazolopyrimidine derivatives

  • Richa Gupta und Ram Pal Chaudhary EMAIL logo
Veröffentlicht/Copyright: 10. Mai 2013

Abstract

The reaction of dihydropyrimidine-2(1H)-thione 4, obtained by the condensation of chalcone 3 with thiourea, with chloroacetic acid and 1,2-dibromoethane furnished compounds 5 and 6 and not their respective isomers 8 and 9. The regiochemistry of the cyclized products and their structure was established by elemental analysis, 1H NMR, 13C NMR, IR and mass spectral data. Density functional theory (DFT) calculations have been carried out for compound 5a and its isomer 8a with Jaguar version 6.5112 using B3LYP density functional method and 6–31G** basis set. 1H and 13C NMR spectra of compound 5a and its possible isomer 8a have been calculated and correlated with experimental results. 2-Arylidene derivatives of 5 were obtained by two routes and their structure was established by spectral data. Compounds 4–7 were screened for their antimicrobial activities.

Introduction

Heterocyclic compounds are highly ranked among pharmaceutically important natural and synthetic materials. The remarkable ability of heterocyclic nuclei to serve as both biomimetics and active pharmacophores has largely contributed to their unique value as traditional key elements of numerous drugs. The thiazolidinone system frequently appears in the structure of various natural products, notably thiamine, compounds possessing cardiac and glycemic benefits such as troglitazone [1] and many metabolic products of fungi and primitive marine animals. Pioglitazone [2] and rosiglitazone are therapeutic agents for the treatment of diabetes [3].

The 4-thiazolidinone system is a core structure in many synthetic compounds exhibiting broad pharmacological spectrum and affinity for various biotargets [4, 5]. Some derivatives are peroxisome proliferator-activated receptor γ (PPAR-γ) agonists showing hypoglycemic activity [6], aldose reductase inhibitors guarding against diabetic complications [7] and cartilage degradation inhibitors [8]. Additionally, 4-thiazolidinone derivatives are reported as anticancer [9, 10], antibacterial [11], anti-HIV [12], anticonvulsant [13], antidiabetic [14] and anti-inflammatory [15] agents.

In continuation of our research program on the synthesis of condensed 4-thiazolidinines [16–18], we report in this paper a novel condensed thiazolo-pyrimidine system. Both thiazole and pyrimidine are bioactive nuclei and it is thought that the condensed system may exhibit enhanced biological activity due to possible synergistic effects. Two novel thiazolo[3,2-a]pyrimidin-3(5H)-one 5 and dihydro-2H-thiazolo[3,2-a]pyrimidine 6 systems are reported. Arylidene derivatives 7 of compounds 5 were also synthesized.

Computational studies

The molecular geometry optimization and 1H and 13C NMR spectra calculations were performed with the Jaguar software package version 6.5112 by using density functional theory (DFT) methods with B3LYP (Becke three parameter Lee-Yang-Parr) exchange correlation functional, which combines the hybrid exchange functional of Becke [19], with the gradient-correlation functional of Lee et al. [20]. The 6–31G** basis set was used for calculations in the gas phase of the structure 5a and its isomer 8a, respectively.

Figure 1 Optimized geometry of compound 5a and its isomer 8a.
Figure 1

Optimized geometry of compound 5a and its isomer 8a.

As the crystal structures of the molecules are not available, DFT calculations were carried out to predict the geometry of the molecules. The optimized bond lengths and bond angles obtained by geometry optimization at B3LYP/6–31G** level of theory for structure 5a are reported in Table 1. For structure 5a, the optimized bond lengths of C=O and S-C in thiazolidinone ring fall in the range of 1.208 Å and 1.856 Å. The optimized bond angles for N-C-O and N-C-S were observed at 122.6° and 126°, respectively. The optimized configurations of structure 5a and its isomer 8a with atom numbering schemes are shown in Figure 1.

Table 1

Selected bond lengths and bond angles of the optimized structure 5a.

Bond lengths (Å)Bond angles (°)
EntryOptimized lengthsEntryOptimized angles
C(21)-H(36)1.11H(36)-C(21)-H(35)109.4
C(8)-H(29)1.10H(36)-C(21)-S(22)112.2
C(11)-N(10)1.46H(36)-C(21)-C(20)108.8
C(20)-N(10)1.46N(10)-C(20)-C(21)118.0
C(9)-N(10)1.47N(10)-C(20)-O(23)122.6
C(8)-C(9)1.49C(21)-C(20)-O(23)122.5
N(12)-C(7)1.45C(19)-C(13)-C(9)121.4
C(11)-N(12)1.26C(7)-N(12)-C(11)115.0
S(22)-C(11)1.85N(10)-C(11)-N(12)126.0
C(21)-S(22)1.82N(12)-C(11)-S(22)126.0
C(20)-C(21)1.50C(11)-N(10)-C(20)124.0
C(20)-O(23)1.20C(11)-N(10)-C(9)108.0
C(9)-H(14)1.11N(10)-C(9)-H(14)107.5
C(5)-C(7)1.50C(8)-C(7)-N(12)120.0

Shielding tensors of structures 5a and 8a were evaluated by using B3LYP functional with basis set given above. To express the chemical shifts in ppm, the geometry of tetramethylsilane (TMS) and chloroform molecules had been optimized and then their 1H and 13C NMR spectra were calculated by the same method using the same basis set as in the case of the calculations on structures 5a and 8a. The shielding of TMS is 32.3379 for 1H NMR and 202.8593 for 13C NMR. The calculated isotropic shielding constants σi were then transformed to chemical shifts relative to TMS by the equation: δi = σTMS – σi.

Figure 2 Plot of the calculated vs. the experimental 1H NMR chemical shifts (ppm).
Figure 2

Plot of the calculated vs. the experimental 1H NMR chemical shifts (ppm).

Figure 3 Plot of the calculated vs. the experimental 13C NMR chemical shifts (ppm).
Figure 3

Plot of the calculated vs. the experimental 13C NMR chemical shifts (ppm).

Experimental and calculated 1H and 13C NMR chemical shifts (ppm) of compounds 5a and its isomer 8a are reported in Tables 2 and 3. The correlation values of proton chemical shifts are found to be 0.9708 for structure 5a and 0.8153 for its isomer 8a (Figure 2). Similarly, the correlation values of carbon chemical shifts of 5a and 8a are found to be 0.9973 and 0.9828, respectively (Figure 3). The theoretical and experimental 1H and 13C data show good correlations for proposed structure 5a and not for 8a. Total energies, zero point energies, HOMO and LUMO energies theoretically obtained for structures 5a and 8a are reported in Table 4. Spectral correlation and energy values support structure 5a for the product and are not consistent for the isomeric structure 8a.

Table 2

Experimental and calculated 1H NMR chemical shifts (ppm) of compound 5a and its isomer 8a.

Table 2 Experimental and calculated 1H NMR chemical shifts (ppm) of compound 5a and its isomer 8a.
Table 3

Experimental and calculated 13C NMR chemical shifts (ppm) of compound 5a and its isomer 8a.

Compound 5aCompound 8a
EntryExpt. NMRCalcd shieldCalcd NMREntryCalcd shieldCalcd NMR
C113273.0785135.64C169.2439139.65
C313771.5494137.24C379.3263129.31
C955151.318953.87C9145.860259.57
C1116149.491160.29C1135.2589175.17
C2018926.6823184.14C225.7554206.01
C2139167.038137.44C21169.214535.16
Table 4

Theoretically computed energies for compounds 5a and 8a.

ParametersCompound 5aCompound 8a
HOMO energy (kcal/mol)-170.01-165.13
LUMO energy (kcal/mol)37.8849.79
Zero point energy (kcal/mol)186.23187.71

Results and discussion

Treatment of chalcone 3a, obtained by the reaction of acetophenone and benzaldehyde, with thiourea in alcoholic KOH gave compound 4a (Scheme 1). The unsymmetrical thione 4a on reaction with chloroacetic acid followed by cyclization of the intermediate in situ was likely to be transformed into compound 5a or 8a or both depending on the mode of cyclization. However, the treatment of thione 4a with chloroacetic acid in the presence of anhydrous sodium acetate in absolute ethanol afforded a single product (thin layer chromatography, TLC) 5a or 8a in 78% yield. The appearance of a band at 1744 cm-1 (C=O) in the IR spectrum, appearance of a peak at δ 189 (C=O) in 13C NMR spectrum and the presence of a molecular ion peak at m/z 307 (63%) in the mass spectrum of the TLC pure product suggested that cyclization had indeed taken place. The IR and mass spectral data were of little help in deciding in favor of either structure 5a or 8a. However, the structure 5a was finally assigned to this cyclization product in preference to structure 8a on the basis of 1H NMR spectral data. Similarly, structure 5b was finally assigned to this cyclization product in preference to structure 8b on the basis of 1H NMR spectral data.

Scheme 1 Synthesis of condensed 4-thiazolidinones (5) and its arylidene derivatives.
Scheme 1

Synthesis of condensed 4-thiazolidinones (5) and its arylidene derivatives.

The reaction of compound 4a with 1,2-dibromoethane gave a product which was purified by column chromatography and could be represented by either structure 6a or 9a. In either structure (6a or 9a), the singlet at δ 5.32 in its 1H NMR spectrum integrating for one proton was assignable to HA. If the structure 8a is correct for the cyclization product, obtained from thione 4a and chloroacetic acid, and then HA would resonate in the same region as that of structure 6a (or 9a). By contrast, if structure 5a is correct, HA will be deshielded by the thiazolidinone ring and consequently HA will resonate downfield in comparison to HA in 6a (or 9a). The appearance of a downfield singlet at δ 5.59 for HA in structure 5a (or 8a) as compared with singlet at δ 5.32 for HA in structure 6a (or 9a) supports structure 5a and is not consistent with structure 8a for which such a downfield shift would not be expected. The deshielding effect is due to the magnetic anisotropy of the C=O group with a minor contribution from the rest of the ring. Similarly, structure 5b was assigned to the final product (not 8b). The same structural conclusion is supported by comparing the chemical shifts of HA of thione 4a with that of cyclization product 5a. The HA proton in thione 4a resonates at δ 5.12, whereas the downfield signal at δ 5.59 (1H, s, HA) in the cyclized product supports structure 5a in preference to structure 8a. Also, from DFT studies (Table 4) structure 5a is preferred over 8a by energy of 1.48 kcal/mol. Arylidene thiazolidinones 7a–d were prepared by two routes. In the first approach thiazolidinone 5 was condensed with aldehydes to give arylidene thiazolidinones, whereas in the second approach compound 7a was obtained directly by heating compound 4a with chloroacetic acid and benzaldehyde. Structures 7a–d were established by IR and 1H NMR spectral data. The parent thiazolidinones 5a and 5b exhibit absorption bands at 1744 and 1744 cm-1 (C=O), but unsaturation at the 2-position being conjugated with the carbonyl group at the 3-position as in arylidene thiazolidinones produces a bathochromic shift [21], as expected; the carbonyl absorption band appears at 1728, 1726 cm-1 in structures 7ab and 1728, 1720 cm-1 in structures 7cd, respectively. The downfield shift in the position of HA in 1H NMR of the product obtained by reaction of 4a with chloroacetic acid may be due to the presence of the imine group in structure 8a. If this is the case then in arylidene derivatives 7ab HA proton will not be affected further because of absence of a conjugated carbonyl group. In the case of arylidene derivatives obtained from 5a the conjugated carbonyl function produces further downfield shift in position of HA in 7ab, that is, δ 6.28 and δ 6.32. This corroborates with structure 5a and is not consistent with 8a. Structure 6 (not 9) for the product, obtained from the reaction of compound 4 with 1,2-dibromoethane, was assigned based on the analogy with structure 5. In a similar way, the structures for compounds 5b and 7b were established by spectral data.

Antimicrobial activity

The newly synthesized compounds 4–7 were tested for antibacterial and antifungal activity. The antimicrobial activity of the compounds was assayed by an antimicrobial susceptibility test [22]. In Petri plates, 100 μL of 24 h growth of each microorganism was spread on the surface of nutrient agar for bacteria and fungi. Then, 50 μL compound at a concentration of 100 μg/mL in dimethyl sulfoxide (DMSO) saturated on discs of 6 mm diameter was kept on the agar surface. The plates were refrigerated for 2 h to allow prediffusion of the compounds from the discs into the seeded agar layer and then incubated at 37°C for 24 h for bacteria and 28°C for 48 h for fungi. Zones of inhibition were measured in mm and size of the disc was subtracted from the zone size to measure final activity. DMSO saturated discs served as solvent control or negative control and streptomycin saturated discs (30 μg) for bacteria and nystatin (30 μg) for fungi as a reference or positive control.

All compounds were found to exhibit moderate antibacterial and antifungal activity against different species of bacteria and fungi. From the activity data (Table 5) it was observed that among all the compounds tested, compounds 5a and 5b show good activity against all the tested bacteria and fungi. Compound 7d shows good activity against Staphylococcus aureus (inhibition 7 mm, standard showed 10 mm) and Bacillus subtilis (inhibition 6 mm, standard showed 8 mm). Other compounds 4a, 4b, 6a, 6b and 7ac show moderate activity against Aspergillus niger and Rhizopus oryzae fungi.

Table 5

Antimicrobial activity studies by disc diffusion method of compounds 4–7.

CompoundZone of inhibition (mm)
Antibacterial activityAntifungal activity
Staphylococcus aureusBacillus subtilisEscherichia coliAspergillus nigerRhizopus oryzae
4a32333
4b33422
5a85673
5b97865
6a43325
6b65237
7a62534
7b54454
7c64325
7d76346
Antibiotica108989
DMSO0000000000

aStreptomycin for bacteria and nystatin for fungi were used at a concentration of 30 μg/mL.

Experimental

Melting points (capillary, sulfuric acid bath) are uncorrected. TLC was performed on silica gel G plates using petroleum ether/ethyl acetate (4:1) as eluent and iodine as a visualizing agent. IR spectra were recorded on an ABB FTIR spectrometer. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO-d6 on a Bruker Advance II 400 NMR spectrometer. Mass spectra were recorded on a TOF MS ES+ 3.56e4 instrument. The elemental analysis of compounds was performed on a Carlo Erba-1108 elemental analyzer. The structures were optimized by molecular mechanics using the PM3 method based on Hyperchem with version 7.5 packages.

General procedure for the synthesis of chalcones 3

A solution of sodium hydroxide (3.1 g, 0.07 mol) in 28 mL of water and 17 mL of ethanol was stirred at 0°C and treated with 7.43 g (0.06 mol) of acetophenone 1 and then with benzaldehyde (6.57 g, 0.06 mol). Stirring was continued at room temperature for an additional 3–4 h. The mixture was left in ice for approximately 10 h. The resultant solid of 3 was filtered, washed with water and crystallized from ethanol [23].

1,3-Diphenyl-2-propen-1-one (3a)

This compound was obtained in 90% yield as a cream colored solid; mp 54–56°C (Lit. mp 42–46°C); IR: υ 1664 (C=O) cm-1; 1H NMR: δ 7.42 (m, 3H, Ar-H and CH), 7.50 (m, 2H, Ar-H), 7.58 (m, 2H, Ar-H), 7.65 (m, 2H, Ar-H), 7.81 (d, 1H, CH, J = 15.7 Hz), 8.03 (m, 2H, Ar-H). Anal. Calcd for C15H12O: C, 86.54; H, 5.77. Found: C, 86.47; H, 5.84.

3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one (3b)

This compound was obtained in 92% yield as a yellow solid; mp 72–74°C (Lit. mp 69–71°C); IR: υ 1658 (C=O) cm-1; 1H NMR: δ 3.85 (s, 3H, OCH3), 6.93 (m, 2H, Ar-H), 7.41 (d, 1H, CH, J = 15.6 Hz), 7.49 (m, 2H, Ar-H), 7.55 (m, 1H, Ar-H), 7.59 (m, 2H, Ar-H), 7.79 (d, 1H, CH, J = 15.6 Hz), 8.01 (m, 2H, Ar-H). Anal. Calcd for C16H14O2: C, 80.67; H, 5.88. Found: C, 80.58; H, 5.94.

General procedure for synthesis of compounds 4

Compound 3 (0.005 mol), and thiourea (0.38 g, 0.005 mol) in ethanolic KOH (1 g in 20 mL ethanol) was heated under reflux for 4 h. The mixture was concentrated to half, and the concentrate was poured into ice-cold water. The resultant solid of 4 was filtered, washed with water and crystallized from ethanol [24].

4,6-Diphenyl-3,4-dihydropyrimidine-2(1H)-thione (4a)

This compound was obtained in 82% yield as a yellow solid; mp 160–162°C; IR: υ 1180 (C=S), 1558 (C=C), 3171 (NH) cm-1; 1H NMR: δ 5.12 (m, 1H, HA), 5.31 (m, 1H, CH), 7.28 (m, 1H, Ar-H), 7.37 (m, 7H, Ar-H), 7.47 (m, 2H, Ar-H), 9.08 (br, 1H, NH, exchangeable with D2O), 9.77 (br, 1H, NH, exchangeable with D2O). Anal. Calcd for C16H14N2S: C, 72.18; H, 5.26; N, 10.53; S, 12.03. Found: C, 72.10; H, 5.34; N, 10.45; S, 12.12.

4-(4-Methoxyphenyl)-6-phenyl-3,4-dihydropyrimidine-2(1H)-thione (4b)

This compound was obtained in 86% yield as a yellow solid; mp 176–178°C; IR: υ 1250 (C=S), 1558 (C=C), 3202 (NH) cm-1; 1H NMR: δ 3.78 (s, 3H, OCH3), 5.13 (m, 1H, HA), 5.19 (m, 1H, CH), 6.88 (m, 2H, Ar-H), 7.28 (m, 2H, Ar-H), 7.36 (m, 3H, Ar-H), 7.49 (m, 2H, Ar-H), 8.75 (br, 1H, NH, exchanged with D2O), 9.05 (br, 1H, NH, exchangeable with D2O). Anal. Calcd for C17H16N2SO: C, 68.92; H, 5.41; N, 9.46; S, 10.81. Found: C, 68.87; H, 5.49; N, 9.54; S, 10.92.

General procedure for synthesis of thiazolidinones 5

A mixture of compound 4 (0.01 mol), chloroacetic acid (0.94 g, 0.01 mol) and anhydrous sodium acetate (0.82 g, 0.01 mol) in absolute ethanol (20 mL) was heated under reflux for 5 h. The mixture was cooled to room temperature and then poured into water. The resultant solid of 5 was filtered, washed with water and crystallized from ethanol.

5,7-Diphenyl-2H-thiazolo[3,2-a]pyrimidin-3(5H)-one (5a)

This compound was obtained in 78% yield as a shining white solid; mp 80–84°C; IR: υ 1744 (C=O), 1651 (C=N) cm-1; 1H NMR: δ 3.90–4.01 (dd, 2H, SCH2, J = 12.6, J = 17.2 Hz), 5.59 (s, 1H, HA), 5.86 (s, 1H, CH), 7.12 (m, 1H, Ar-H); 7.22 (m, 1H, Ar-H); 7.28 (m, 2H, Ar-H); 7.35 (m, 5H, Ar-H); 7.82 (d, 1H, Ar-H, J = 7.5 Hz); 13C NMR: δ 189, 161, 144, 137, 132, 130, 128, 127, 119, 114, 55, 40, 39; MS: m/z 307 (M+H+, 63%). Anal. Calcd for C18H14N2SO: C, 70.59; H, 4.58; N, 9.15; S, 10.46. Found: C, 70.65; H, 4.65; N, 9.24; S, 10.52.

5-(4-Methoxyphenyl)-7-phenyl-2H-thiazolo[3,2-a]pyrimidin-3(5H)-one (5b)

This compound was obtained in 80% yield as a white solid; mp 100–102°C; IR: υ 1744 (C=O), 1612 (C=N) cm-1; 1H NMR: δ 3.84 (s, 3H, OCH3), 4.62 (dd, 2H, SCH2, J = 5.7 Hz, J = 7.4 Hz), 6.95 (s, 1H, HA), 6.97 (s, 1H, CH), 7.52 (t, 2H, Ar-H, J = 7.4 Hz), 7.60 (m, 2H, Ar-H), 7.72 (m, 3H, Ar-H), 8.05 (m, 2H, Ar-H); 13C NMR: δ 170, 159, 155, 139, 134, 131, 129, 127, 126, 121, 113, 111, 54, 40, 39, 38, 31, 28, 27; MS: m/z 337 (M+H+, 70%). Anal. Calcd for C19H16N2SO2: C, 67.86; H, 4.76; N, 8.33; S, 9.52. Found: C, 67.76; H, 4.85; N, 8.27; S, 9.59.

General procedure for synthesis of compounds 6

A mixture of thione 4 (0.01 mol) and 1,2-dibromoethane (5.0 mL) was stirred at 110°C for 4 h. The crude solid 6 was purified by silica gel column chromatography using petroleum ether/ethyl acetate (4:1) as an eluent.

5,7-Diphenyl-3,5-dihydro-2H-thiazolo[3,2-a]pyrimidine (6a)

This compound was obtained in 65% yield as a brown solid; mp 140–142°C; IR: υ 1673 (C=N) cm-1; 1H NMR: δ 2.42 (t, 2H, SCH2, J = 7.8 Hz), 3.52 (t, 2H, NCH2, J = 7.9 Hz), 5.32 (s, 1H, HA), 5.64 (s, 1H, CH), 7.20 (m, 10H, C6H5); 13C NMR: δ 165, 138, 131, 129, 128, 127, 125, 103, 59, 52, 40, 39, 38, 31, 30, 28, 22, 13; MS: m/z 293 (M+H+, 100%). Anal. Calcd for C18H16N2S: C, 73.97; H, 5.48; N, 9.59; S, 10.96. Found: C, 73.88; H, 5.54; N, 9.50; S, 10.88.

5-(4-Methoxyphenyl)-7-phenyl-3,5-dihydro-2H-thiazolo[3,2-a]pyrimidine (6b)

This compound was obtained in 62% yield as a yellow solid; mp 160–162°C; IR: υ 1672 (C=N) cm-1; 1H NMR:δ 2.84–2.87 (t, 2H, SCH2, J = 6 Hz), 2.95–2.98 (t, 2H, NCH2, J = 6 Hz), 3.79 (s, 3H, OCH3), 5.72 (d, 1H, HA, J = 10 Hz), 5.75–5.77 (d, 1H, CH, J = 8 Hz), 6.84–6.87 (m, 2H, Ar-H), 6.91 (d, 2H, Ar-H, J= 4 Hz), 7.10–7.14 (m, 1H, Ar-H), 7.25–7.27 (d, 1H, Ar-H, J = 7 Hz), 7.47 (m, 3H, Ar-H); 13C NMR: δ 165, 160, 132, 131, 130, 129, 128, 126, 125, 114, 103, 59, 55, 52, 40, 39, 31, 30, 27, 22, 14; MS: m/z 323 (M+H+, 100%). Anal. Calcd for C19H18N2SO: C, 70.81; H, 5.59; N, 8.70; S, 9.94. Found: C, 70.92; H, 5.67; N, 8.81; S, 9.88.

General procedure for synthesis of arylidene derivatives (7)

These compounds were prepared by two routes. (i) A mixture of thiazolidinone 5 (0.001 mol), aromatic aldehyde (0.001 mol) and anhydrous sodium acetate (0.082 g, 0.001 mol) in glacial acetic acid (10 mL) was heated under reflux for 4 h. The mixture was cooled to room temperature and poured into water. The solid thus obtained was filtered and washed with water and crystallized from dimethylformamide and ethanol mixture (1:1) to give compound 7. (ii) A mixture of thione 4a (0.001 mol), chloroacetic acid (0.094 g, 0.001 mol) and aromatic aldehyde (0.001 mol) and anhydrous sodium acetate (0.082 g, 0.001 mol) in glacial acetic acid (10 mL) and acetic anhydride (1 mL) was heated under reflux for 3–4 h. A similar work up as in (i) gave compound 7a.

(E)-2-Benzylidene-5,7-diphenyl-2H-thiazolo[3,2-a]pyrimidin-3(5H)-one (7a)

This compound was obtained in 70% yield as a shining yellow solid; mp 212–214°C; IR: υ 1728 (C=O), 1582 (C=N) cm-1; 1H NMR: δ 6.28 (s, 1H, HA), 6.72 (s, 1H, CH), 7.47 (m, 4H, Ar-H), 7.55 (m, 11H, Ar-H), 7.05 (s, 1H, HB). Anal. Calcd for C25H18N2SO: C, 76.14; H, 4.57; N, 7.11; S, 8.12. Found: C, 76.22, H, 4.62; N, 7.06; S, 8.20.

(E)-2-(4-Methylbenzylidene)-5,7-diphenyl-2H-thiazolo[3,2-a]pyrimidin-3(5H)-one (7b)

This compound was obtained in 72% yield as yellow needles; mp 202–204°C; IR: υ 1726 (C=O), 1598 (C=N) cm-1; 1H NMR: δ 2.38 (s, 3H, CH3), 6.26 (s, 1H, HA), 6.78 (s, 1H, CH), 7.43 (m, 14H, Ar-H), 7.97 (s, 1H, HB). Anal. Calcd for C26H20N2SO: C, 76.47; H, 4.90; N, 6.86; S, 7.84. Found: C, 76.52; H, 4.82; N, 6.92; S, 7.78.

(E)-2-Benzylidene-5-(4-methoxyphenyl)-7-phenyl-2H-thiazolo[3,2-a]pyrimidin-3(5H)-one (7c)

This compound was obtained in 66% yield as a light yellow solid; mp 238–240°C; IR: υ 1728 (C=O), 1582 (C=N) cm-1; 1H NMR: δ 3.71 (s, 3H, OCH3), 6.32 (s, 1H, HA), 6.78 (s, 1H, CH), 7.04 (m, 2H, Ar-H), 7.34 (s, 1H, HB), 7.49 (m, 12H, Ar-H), 7.77 (s). Anal. Calcd for C26H20N2SO2: C, 73.58; H, 4.72; N, 6.60; S, 7.55. Found: C, 73.64; H, 4.68; N, 6.69; S, 7.49.

(E)-5-(4-Methoxyphenyl)-2-(4-methylbenzylidene)-7-phenyl-2H-thiazolo[3,2-a]pyrimidin-3(5H)-one (7d)

This compound was obtained in 68% yield as a yellow solid; mp 248–250°C; IR: υ 1720 (C=O), 1574 (C=N) cm-1; 1H NMR: δ 2.37 (s, 3H, CH3), 3.70 (s, 3H, OCH3), 6.33 (m, 1H, HA), 6.83 (s, 1H, CH), 7.04–7.07 (m, 2H, Ar-H), 7.11–7.13 (m, 2H, Ar-H), 7.18–7.20 (m, 3H, Ar-H), 7.43–7.45 (m, 6H, Ar-H), 7.68 (s, 1H, HB). Anal. Calcd for C27H22N2SO2: C, 73.97; H, 5.02; N, 6.39; S, 7.31. Found: C, 73.88; H, 5.10; N, 6.30; S, 7.40.


Corresponding author: Ram Pal Chaudhary, Department of Chemistry, Sant Longowal Institute of Engineering and Technology, Longowal (Sangrur), Punjab 148106, India

R.G. is thankful to the authorities of Sant Longowal Institute of Engineering and Technology, Longowal for providing financial assistance. The facilities provided by SLIET authorities are gratefully acknowledged.

References

[1] Ghazzi, M. N.; Perez, J. E.; Antonucci, T. K.; Driscoll, J. H.; Huang, S. M.; Faja, B. W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The troglitazone study group. Diabetes1997, 46, 433–439.Suche in Google Scholar

[2] Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on antidiabetic agents X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull. 1991, 39, 1440–1445.Suche in Google Scholar

[3] Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Du, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem.1994, 37, 3977–3985.Suche in Google Scholar

[4] Lesyk, R. B.; Zimenkovsky, B. S. 4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry. Curr. Org. Chem. 2004, 8, 1547–1577.Suche in Google Scholar

[5] Verma, A.; Saraf, S. K. 4-Thiazolidinone – a biologically active scaffold. Eur. J. Med. Chem. 2008, 43, 897–905.Suche in Google Scholar

[6] Kumar, B. R. P.; Nanjan, M. J. Novel glitazones: design, synthesis, glucose uptake and structure-activity relationships. Bioorg. Med. Chem. Lett. 2010, 20, 1953–1956.Suche in Google Scholar

[7] Carbone, V.; Giglio, M.; Chung, R.; Huyton, T.; Adams, J.; Maccari, R.; Ottana, R.; Hara, A.; El-Kabbani, O. Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor. Eur. J. Med. Chem. 2010, 45, 1140–1145.Suche in Google Scholar

[8] Panico, A. M.; Vicini, P.; Geronikaki, A.; Incerti, M.; Cardile, V.; Crasci, L.; Messina, R.; Ronsisvalle, S. Heteroarylimino-4-thiazolidinones as inhibitors of cartilage degradation. Bioorg. Chem. 2011, 39, 48–52.Suche in Google Scholar

[9] Li, Q.; Wua, J.; Zheng, H.; Liu, K.; Guo, T. L.; Liu, Y.; Eblen, S. T.; Grant, S.; Zhang, S. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorg. Med. Chem. Lett. 2010, 20, 4526–4530.Suche in Google Scholar

[10] Kamel, M. M.; Ali, H. I.; Anwar, M. M.; Mohamed, N. A.; Soliman, A. M. Synthesis, antitumor activity and molecular docking study of novel sulfonamide-Schiff’s bases, thiazolidinones, benzothiazinones and their C-nucleoside derivatives. Eur. J. Med. Chem. 2010, 45, 572–580.Suche in Google Scholar

[11] Liu, X. F.; Zheng, C. J.; Sun, L. P.; Liu, X. K.; Piao, H. R. Synthesis of new chalcone derivatives bearing 2,4-thiazolidinonedione and benzoic acid moieties as potential antibacterial agents. Eur. J. Med. Chem. 2011, 46, 3469–3473.Suche in Google Scholar

[12] Tian, Y.; Zhan, P.; Rai, D.; Zhang, J.; De Clercq, E.; Liu, X. Recent advances in the research of 2,3-diaryl-1,3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem. 2012, 19, 2026–2037.Suche in Google Scholar

[13] Siddiqui, N.; Arshad, M. F.; Khan, S. A.; Ahsan, W. Sulfonamide derivatives of thiazolidin-4-ones with anticonvulsant activity against two seizure models: synthesis and pharmacological evaluation. J. Enzyme Inhib. Med. Chem. 2010, 25, 485–491.Suche in Google Scholar

[14] Faidallah, H. M.; Khan, K. A.; Asiri, A. M. Synthesis and biological evaluation of new 3-trifluoromethylpyrazolesulfonyl-urea and thiourea derivatives as antidiabetic and antimicrobial agents. J. Fluorine Chem. 2011, 132, 131–137.Suche in Google Scholar

[15] Kumar, V.; Sharma, A.; Sharma, P. C. Synthesis of some novel 2,5-disubstituted thiazolidinones from a long chain fatty acid as possible anti-inflammatory, analgesic and hydrogen peroxide scavenging agents. J. Enzyme Inhib. Med. Chem. 2011, 26, 198–203.Suche in Google Scholar

[16] Gupta, R.; Chaudhary, R. P. Ionic liquid-mediated facile synthesis and antimicrobial study of thiazolo[2,3-b] benzo[h]quinazolines and thiazino[2,3-b]benzo-[h]quinazolines. Phosphorus Sulfur Silicon Relat. Elem. 2012, 187, 735–742.Suche in Google Scholar

[17] Gautam, D.; Gautam, P.; Chaudhary, R. P. Efficient synthesis of 2,4-disubstituted thiazoles and 2-substituted 4-thiazolidinones under solvent free conditions. Heterocycl. Commun. 2011, 17, 147–150.Suche in Google Scholar

[18] Gupta, R.; Chaudhary, R. P. N-Methylpyridinium tosylate catalysed green synthesis, X-ray studies and antimicrobial activities of novel (E)-3-amino-2-(E)-(3,4-dihydronaphthalen-1(2H)-ylidene)hydrazono)thiazolidin-4-ones. Phosphorus Sulfur Silicon Relat. Elem. 2012, [EPub Ahead of Print] Doi: 10.1080/10426507.2012.729235.10.1080/10426507.2012.729235Suche in Google Scholar

[19] Becke, A. D. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys. Rev. A1988, 38, 3098–3100.10.1103/PhysRevA.38.3098Suche in Google Scholar

[20] Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B1988, 37, 785–789.Suche in Google Scholar

[21] Randall, H. M.; Fowler, R. G.; Fuson, N.; Dangl, J. R. Infrared Determination of Organic Structures; Van Nostrand: New York, 1949.Suche in Google Scholar

[22] Arthington-Skaggs, B. A.; Motley, M.; Warnock, D. W.; Morrison, C. J. Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts. J. Clin. Microbiol. 2000, 38, 2254–2260.Suche in Google Scholar

[23] Palleros, D. R. Solvent-free synthesis of chalcones. J. Chem. Educ. 2004, 81, 1345–1347.Suche in Google Scholar

[24] Gupta, R.; Chaudhary, R. P. Efficient ionic liquid-catalyzed synthesis and antimicrobial studies of 4,6-diaryl- and 4,5-fused pyrimidine-2-thiones. J. Chem. Res. 2012, 36, 718–721.Suche in Google Scholar

Received: 2013-2-7
Accepted: 2013-3-2
Published Online: 2013-05-10
Published in Print: 2013-06-01

©2013 by Walter de Gruyter Berlin Boston

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Heruntergeladen am 12.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hc-2013-0024/html
Button zum nach oben scrollen